Replies to post #191244 on NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

I never said that warrants were positive for existing shareholders. They add to share count after exercising. But they can be attractive to buyers, as they provide cash that can be used for financing. If NWBO could get above the average warrant exercise price, the company would generate cash that could be used for corporate purposes. Market price on NWBO hasn’t been above average warrant exercise price in years, leaving many warrants to expire worthless and the company cash deficient. All that changes in a buyout. A potential low offer buyout could actually be financed with existing warrant money as a down payment.

[Barunuuk]

No buyout - Lets get this straight. At this point, there will not be a buyout. If there is a buyout, then the trial will have been negative. NWBO is so close to the end of its P3 trial that there is no chance for a buyout. And if the results are positive, then any type of buyout would be $10B or higher (AND with positive results it would be much much higher than $10B), marking the share cost at greater than $20 per share.